Navigation Links
Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Date:6/28/2010

to 45, with newly diagnosed autoimmune type 1 diabetes. DEFEND-1 is being conducted at over 100 study centers throughout Europe and North America.  The study is designed to evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will preserve beta cell function as measured by C-peptide, a surrogate measure of beta cell function.  The primary endpoint is measurement of C-peptide.  For more information about DEFEND, please visit www.DefendAgainstDiabetes.com.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level.  There are two major types of diabetes:  type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder involving the body's immune system.  In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas.  As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels. 

About Otelixizumab

Otelixizumab is a targeted T cell immunomodulator being developed for the treatment of type 1 diabetes and other autoimmune diseases.  Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling.  Otelixizumab has not yet been approved for marketing. Data suggest that the anti
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
2. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
3. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
4. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
5. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
6. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
9. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
10. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
11. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... YORK , July 25, 2014  Smile Train ... to showcase their Virtual Surgery Simulator among leading ... which will take place in Washington, D.C. ... the Performing Arts. "Smile Train is ... alongside the talented community of innovators in health and ...
(Date:7/25/2014)... -- GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to announce ... LaurelCo, LLC, an Illinois limited liability ... dispensary medical marijuana licenses in the state of ... a 20% equity interest in LaurelCo, LLC in exchange for ... as well as all technology related to the machines and ...
(Date:7/25/2014)... -- Solanbridge Group Inc (OTC: SLNX) is pleased to announce ... and the Letter of Intent issued on July 11, ... Agreement. Charles R. Shirley , Managing ... Mr. David Pecoraro and Buzznbrewz.com join SLNX,s ... sector and developed a tremendous network of contacts who ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... LOUIS, Aug. 30, 2011 The Board of Directors of ... its regularly scheduled board meeting that it reaffirmed the Company,s ... platform and expansion of the Odyssey ™  platform into ... Board reviewed and endorsed the commercial strategies put forth for ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, announced today that Arthur T. ... officer, will present at the Stifel Nicolaus Healthcare Conference ... p.m. Eastern Time.  Dr. Sands will provide an overview ...
Cached Medicine Technology:Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 2Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 3Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference 2
(Date:7/28/2014)... July 28, 2014 Mitul R. Patel, ... gathered at the MGE Management Experts Benefit Dinner May ... leaders joined the Dentists to raise funds for the ... and Girls Clubs and Youth Programs across America. The ... people with books and audio books to directly tackle ...
(Date:7/28/2014)... 2014 Dr. Alan Xenakis, MD announced today ... Funny Feelings.” The new book, DOC X MD Funny ... unique story telling style with humor and medical accuracy. The ... reader will find answers to those age-old questions that most ... people pee? Why do mosquitoes bite some and not others? ...
(Date:7/27/2014)... Zensah®, the leader in compression technology and sports medicine, has ... . The wrist support features an adjustable velcro strap and ... Epicondylitis, more commonly referred to as tennis elbow and golfers ... the tendons attached to the outside of the elbow. Although ... work the wrist and fingers turn into a tendon that ...
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are now ... younger appearance. The Cherry News company has published its ... women explore the availabilities from U.S. retailers at ... the posted guide on the Cherry News website provide ... to some natural ingredient formulas is the high sticker ...
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
Breaking Medicine News(10 mins):Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... play a role in screening for colorectal cancer (CRC), ... rates, the American Gastroenterological Association (AGA) Institute issued minimum ... competence, a minimum of 75 endoscopically confirmed cases should ... fact that CT colonography has not yet been endorsed ...
... than other chronic conditions , , FRIDAY, Sept. 7 (HealthDay ... may well be the most disabling disease in the ... chronic physical diseases such as angina, arthritis, asthma and ... from depression, the team of international researchers found. , ...
... Home and the ... Workplace-- ... Sept. 7 Quick, convenient, quality,health care has come to the Oklahoma ... the CVS/pharmacy store in Moore at 1040,SW 19th Street. MinuteClinic ( http://www.minuteclinic.com ...
... Group, the,international generic pharmaceuticals company, today announced that ... from the U.S. Food &,Drug Administration. Distribution of ... tablets, the generic equivalent of Pfizer,s,Norvasc(R) tablets, will ... 10 mg strengths,and are indicated for the treatment ...
... BELLEVILLE, ON, Sept. 7 /PRNewswire-FirstCall/ - Bioniche ... Canadian,biopharmaceutical company, today announced that it has ... Economic Development (RED) Program of the,Ontario Ministry ... grant,announced by the Honourable Leona Dombrowsky, Minister ...
... Medicine at The University of Nottingham, has been recognised ... of newborn babies, particularly those born prematurely, with an ... award, by the Good Clinical Practice Journal (GCPj), acknowledges ... in drug development and clinical trials. It is given ...
Cached Medicine News:Health News:Gastroenterology sets standards for CT colonography 2Health News:Gastroenterology sets standards for CT colonography 3Health News:Depression May Be World's Most Disabling Disease 2Health News:Depression May Be World's Most Disabling Disease 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 2Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 4Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 5Health News:Actavis Launches Amlodipine Tablets in the U.S. 2Health News:Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine 2Health News:Academic Researcher of the Year 2007 2
... Alsius heat exchange catheters connect to the ... and maintains a target temperature input by ... patient core temperature and automatically adjusts the ... catheter (0-42C), providing consistent maintenance of temperature. ...
... vascular access. Hollow stylet design ... puncture with two-part needle. Initial ... while maintaining thumb position on ... hub of the stylet. Supplied ...
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for percutaneous introduction of balloon, electrode and closed or non-tapered end catheters for vascular and non-vascular use....
Medicine Products: